Healthcare provider profile · identity verified

Jane A Ware, MD

Internal Medicine · PORTLAND, OR · NPI 1891011532

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	258	59
Amlodipine Besylate	Amlodipine Besylate	157	46
Levothyroxine Sodium	Levothyroxine Sodium	145	31
Omeprazole	Omeprazole	122	30
Metoprolol Succinate	Metoprolol Succinate	111	30
Gabapentin	Gabapentin	104	24
Lisinopril	Lisinopril	98	30
Losartan Potassium	Losartan Potassium	98	24
Lovastatin	Lovastatin	80	25
Hydrochlorothiazide	Hydrochlorothiazide	76	19
Eliquis	Apixaban	68	19
Metformin Hcl Er	Metformin Hcl	68	14
Ozempic	Semaglutide	68	12
Escitalopram Oxalate	Escitalopram Oxalate	63	19
Pravastatin Sodium	Pravastatin Sodium	62	17
Trazodone Hcl	Trazodone Hcl	54	15
Rosuvastatin Calcium	Rosuvastatin Calcium	53	17
Tamsulosin Hcl	Tamsulosin Hcl	50	15
Bupropion Xl	Bupropion Hcl	47	14
Estradiol	Estradiol	45	20
Potassium Chloride	Potassium Chloride	38	suppressed
Simvastatin	Simvastatin	38	suppressed
Duloxetine Hcl	Duloxetine Hcl	37	suppressed
Valsartan	Valsartan	37	13
Acyclovir	Acyclovir	35	suppressed
Allopurinol	Allopurinol	34	suppressed
Jardiance	Empagliflozin	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	32	suppressed
Atenolol	Atenolol	31	suppressed
Sertraline Hcl	Sertraline Hcl	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	12
Oxycodone Hcl	Oxycodone Hcl	30	suppressed
Propranolol Hcl Er	Propranolol Hcl	30	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	29	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	29	suppressed
Propranolol Hcl	Propranolol Hcl	29	suppressed
Montelukast Sodium	Montelukast Sodium	28	suppressed
Mirtazapine	Mirtazapine	26	11
Pregabalin	Pregabalin	26	suppressed
Meloxicam	Meloxicam	25	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	25	suppressed
Famotidine	Famotidine	24	suppressed
Furosemide	Furosemide	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Terbinafine Hcl	Terbinafine Hcl	23	suppressed
Carvedilol	Carvedilol	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	11
Nortriptyline Hcl	Nortriptyline Hcl	21	suppressed
Buspirone Hcl	Buspirone Hcl	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	18	suppressed
Felodipine Er	Felodipine	18	suppressed
Finasteride	Finasteride	18	suppressed
Telmisartan	Telmisartan	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Metformin Hcl	Metformin Hcl	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Progesterone	Progesterone, Micronized	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Prednisone	Prednisone	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error